OBJECTIVES: To measure the efficacy and toxic effects of our chemoradiotherapy regimen by means of response and survival in @entity1 with advanced @entity957 of the @entity135 ( @entity213 ) for organ preservation in resectable disease or palliation in unresectable disease. DESIGN: All @entity1 underwent evaluation by the @entity135 team, with pathological diagnosis and @entity5 . All @entity1 underwent assessment for response to therapy using results of physical examination and radiologic imaging. @entity1 were followed up at 3-month intervals for a planned period of 5 years. SETTING: @entity4207 center. @entity1 : Thirty-eight previously untreated @entity1 with newly diagnosed @entity213 were treated from June 1, 1996, through December 31, 1998, of whom 20 had resectable and 18 had unresectable @entity5 . INTERVENTION: @entity1 received intravenous @entity900 , 100 mg/m(2) for 1 hour on days 1 and 29; a 24-hour continuous infusion of @entity1487 , 1000 mg/m(2) on days 1 through 4 and 29 through 32; and radiation therapy, 150 rad twice daily for 12 days. The @entity1 were given a 7- to 10-day break, and radiation therapy was restarted on day 29 for 12 additional days (total dose, 7200 rad). MAIN OUTCOME MEASURES: Complete, partial, and total response rates; disease-free survival; overall survival; and toxic effects. RESULTS: Toxic effects of treatment were moderately severe, including grades III to IV @entity33 (89%), @entity1398 (71%), and renal toxic effects (8%). In the 18 @entity1 in the unresectable group, complete response in the 17 primary @entity5 and 15 cervical nodal metastases was achieved in 12 (71%) and 9 (60%), respectively; in the 20 @entity1 undergoing organ preservation, complete response rates were 100% in the 23 primary @entity5 and 15 cervical nodal metastases. Complete response for all 38 @entity1 was achieved in 31 (82%). In the unresectable group, the Kaplan-Meier relapse-free survival estimate is 56%, with follow-up from 29 to 45 months. In the organ preservation group, 75% of @entity1 are alive without disease, and 8 have been followed up for 36 to 48 months. Of the 5 @entity1 who have died, only 2 died of disease, with recurrences at 13.0 and 16.5 months. CONCLUSIONS: Chemoradiotherapy consisting of @entity900 , @entity1487 , and twice-daily external beam radiation is highly effective in achieving durable complete responses in @entity1 with resectable @entity213 undergoing organ preservation and @entity1 with unresectable @entity213 undergoing palliation. Toxic effects of this regimen were moderate to severe.

Chemoradiation for locally advanced @entity957 of the XXXX for organ preservation and palliation.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck', 'multidisciplinary head and neck cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['staging', 'tumors'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil'] @entity4207 :: ('MESH:D007859', 'Disease') :: ['Academic'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HNSCC']
@entity135 :: (MESH:D006258,Disease) :: ['head and neck']
